Nathan M. Belliveau

Learn More
Lipid nanoparticles (LNP) are the leading systems for in vivo delivery of small interfering RNA (siRNA) for therapeutic applications. Formulation of LNP siRNA systems requires rapid mixing of solutions containing cationic lipid with solutions containing siRNA. Current formulation procedures employ macroscopic mixing processes to produce systems 70-nm(More)
Lipid nanoparticles (LNP) containing ionizable cationic lipids are the leading systems for enabling therapeutic applications of siRNA; however, the structure of these systems has not been defined. Here we examine the structure of LNP siRNA systems containing DLinKC2-DMA(an ionizable cationic lipid), phospholipid, cholesterol and a polyethylene glycol (PEG)(More)
A mistake has been found in the article on page 18444. The second paragraph should read: " Here we explored whether limit size particles compatible with such structures could be generated using PEG-lipid as the surface lipid. In this regard a vesicle containing an internal aqueous core of 5 nm diameter has an outside-to-inside surface area ratio of 6.8(More)
  • 1